DURHAM, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK; NHWK), an integrated contract development and manufacturing organization (CDMO), today announced that it is changing the name of the Company to Scorpius Holdings, Inc. (“Scorpius”) to better reflect the Company’s successful shift into a pure-play, large molecule biomanufacturing CDMO.

北卡罗来纳州达勒姆，2024年1月8日（环球通讯社）--夜鹰生物科学公司（纽约证券交易所美国证券交易所：NHWK；NHWK），一家综合合同开发和制造组织（CDMO），今天宣布将公司更名为天蝎座控股公司（“天蝎座”），以更好地反映公司成功转变为纯粹的大分子生物制造CDMO。

The Company will continue to operate its CDMO within the Scorpius BioManufacturing subsidiary. In connection with the name change, the Company’s ticker will change to SCPX as well. The name and symbol changes will not affect the Company's share structure or the rights of the Company's shareholders, and no further action will be required by existing shareholders.

该公司将继续在Scorpius生物制造子公司内运营CDMO。在名称变更方面，该公司的股票代码也将更改为SCPX。名称和符号的变更不会影响公司的股权结构或公司股东的权利，现有股东无需采取进一步行动。

In addition, the Company announced that it has bolstered its leadership team with the promotions of Brian O’Mara to VP of Process Sciences and Steve Lavezoli to VP of Commercial Operations, as well as the additions of Juan Lagos as Senior Director of Cell-Based Technologies and Ania Szymanska as Site Head of Quality.

此外，该公司宣布，通过将布莱恩·奥马拉（BrianO'Mara）晋升为过程科学副总裁，史蒂夫·拉维佐利（SteveLavezoli）晋升为商业运营副总裁，以及任命胡安·拉各斯（JuanLagos）为基于细胞的技术高级总监，安妮娅·西曼斯卡（AniaSzymanska）为现场质量总监，增强了其领导团队。

Jeff Wolf, CEO of Nighthawk, commented, “Our rebranding to Scorpius Holdings is a testament to our successful transition and the growth of our CDMO operations. The industry faces a critical shortage of clinical-scale biologic manufacturing capacity, driven by increasing demand for large molecule CDMO services.

夜鹰首席执行官杰夫·沃尔夫（Jeff Wolf）评论道：“我们更名为天蝎座控股公司（Scorpius Holdings）证明了我们的成功转型和CDMO业务的增长。由于对大分子CDMO服务的需求不断增加，该行业面临着临床规模生物制造能力的严重短缺。

Our state-of-the-art facility in San Antonio, Texas ideally positions us to address this gap in CDMO manufacturing capacity and services. The response from major biotech companies and leading research institutions to our CDMO capabilities has been positive, as evidenced by the expansion of our sales pipeline.' Mr.

我们位于德克萨斯州圣安东尼奥的最先进的设施使我们能够解决CDMO制造能力和服务方面的这一差距。主要生物技术公司和领先研究机构对我们CDMO能力的反应是积极的，我们销售渠道的扩大证明了这一点。”先生。

Wolf further noted, “To better service increasing demand for our specialized CDMO services, we have expanded.

沃尔夫进一步指出，“为了更好地服务不断增长的对我们专业CDMO服务的需求，我们已经扩大了规模。